U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Ovarian Endometrioid Adenocarcinoma

MedGen UID:
1666787
•Concept ID:
C4725615
•
Neoplastic Process
Synonym: Recurrent Ovarian Endometrioid Carcinoma

Definition

The reemergence of ovarian endometrioid adenocarcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Ovarian Endometrioid Adenocarcinoma

Professional guidelines

PubMed

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
J Clin Oncol 2020 Oct 20;38(30):3468-3493. Epub 2020 Aug 13 doi: 10.1200/JCO.20.01924. PMID: 32790492Free PMC Article
Risk-stratifying clinicopathologic criteria for ovarian preservation in premenopausal women with early stage low-risk endometrial cancer.
Khadraoui W, Tierney C, Chung S, Mutlu L, Lu L, Azodi M, Ratner E, Menderes G
Int J Gynaecol Obstet 2020 Sep;150(3):385-391. Epub 2020 Jun 26 doi: 10.1002/ijgo.13254. PMID: 32506422
Management of newly diagnosed or recurrent ovarian cancer.
Matulonis UA
Clin Adv Hematol Oncol 2018 Jun;16(6):426-437. PMID: 30067614

Recent clinical studies

Etiology

Ovarian preservation in gynecologic oncology: current indications and techniques.
Bizzarri N, Pavone M, Loverro M, Querleu D, Fagotti A, Scambia G
Curr Opin Oncol 2023 Sep 1;35(5):401-411. Epub 2023 Jul 13 doi: 10.1097/CCO.0000000000000969. PMID: 37498120
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL
Lancet Oncol 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. PMID: 32359490Free PMC Article
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, Ør Knudsen A, Staff S, Krog Vistisen A, Bjørge L, Mäenpää JU; AVANOVA investigators
Lancet Oncol 2019 Oct;20(10):1409-1419. Epub 2019 Aug 29 doi: 10.1016/S1470-2045(19)30515-7. PMID: 31474354
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article

Diagnosis

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
J Clin Oncol 2020 Oct 20;38(30):3468-3493. Epub 2020 Aug 13 doi: 10.1200/JCO.20.01924. PMID: 32790492Free PMC Article
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL
Lancet Oncol 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. PMID: 32359490Free PMC Article
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, Ør Knudsen A, Staff S, Krog Vistisen A, Bjørge L, Mäenpää JU; AVANOVA investigators
Lancet Oncol 2019 Oct;20(10):1409-1419. Epub 2019 Aug 29 doi: 10.1016/S1470-2045(19)30515-7. PMID: 31474354
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article

Therapy

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
J Clin Oncol 2020 Oct 20;38(30):3468-3493. Epub 2020 Aug 13 doi: 10.1200/JCO.20.01924. PMID: 32790492Free PMC Article
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL
Lancet Oncol 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. PMID: 32359490Free PMC Article
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, Ør Knudsen A, Staff S, Krog Vistisen A, Bjørge L, Mäenpää JU; AVANOVA investigators
Lancet Oncol 2019 Oct;20(10):1409-1419. Epub 2019 Aug 29 doi: 10.1016/S1470-2045(19)30515-7. PMID: 31474354
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article

Prognosis

Correlation of clinicopathological and prognostic characteristics between endometriosis-associated and primary ovarian cancer.
Wang H, Chen C, Wang D, Zhu Y, Chen P
BMC Cancer 2023 Dec 8;23(1):1210. doi: 10.1186/s12885-023-11641-4. PMID: 38066448Free PMC Article
Synchronous endometrial and ovarian cancer and its recurrent risk factors: Case series.
Hoorshad N, Nassiri S, Najibi S, Feizabad E, Zamani N
Cancer Treat Res Commun 2023;36:100731. Epub 2023 Jun 25 doi: 10.1016/j.ctarc.2023.100731. PMID: 37429245
Endometrioid Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Managements.
Ricotta G, Maulard A, Candiani M, Scherrier S, Genestie C, Pautier P, Leary A, Chargari C, Mangili G, Morice P, Gouy S
Ann Surg Oncol 2022 Sep;29(9):5894-5903. Epub 2022 May 19 doi: 10.1245/s10434-022-11893-7. PMID: 35590116
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
Management and prognosis of endometrioid borderline tumors of the ovary.
Uzan C, Berretta R, Rolla M, Gouy S, Fauvet R, Darai E, Duvillard P, Morice P
Surg Oncol 2012 Sep;21(3):178-84. Epub 2012 Mar 13 doi: 10.1016/j.suronc.2012.02.002. PMID: 22418038

Clinical prediction guides

Synchronous endometrial and ovarian cancer and its recurrent risk factors: Case series.
Hoorshad N, Nassiri S, Najibi S, Feizabad E, Zamani N
Cancer Treat Res Commun 2023;36:100731. Epub 2023 Jun 25 doi: 10.1016/j.ctarc.2023.100731. PMID: 37429245
Endometrioid Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Managements.
Ricotta G, Maulard A, Candiani M, Scherrier S, Genestie C, Pautier P, Leary A, Chargari C, Mangili G, Morice P, Gouy S
Ann Surg Oncol 2022 Sep;29(9):5894-5903. Epub 2022 May 19 doi: 10.1245/s10434-022-11893-7. PMID: 35590116
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, Ør Knudsen A, Staff S, Krog Vistisen A, Bjørge L, Mäenpää JU; AVANOVA investigators
Lancet Oncol 2019 Oct;20(10):1409-1419. Epub 2019 Aug 29 doi: 10.1016/S1470-2045(19)30515-7. PMID: 31474354
MicroRNA and gynecological reproductive diseases.
Santamaria X, Taylor H
Fertil Steril 2014 Jun;101(6):1545-51. doi: 10.1016/j.fertnstert.2014.04.044. PMID: 24882618

Recent systematic reviews

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
J Clin Oncol 2020 Oct 20;38(30):3468-3493. Epub 2020 Aug 13 doi: 10.1200/JCO.20.01924. PMID: 32790492Free PMC Article
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
J Clin Oncol 2020 Apr 10;38(11):1222-1245. Epub 2020 Jan 27 doi: 10.1200/JCO.19.02960. PMID: 31986064Free PMC Article
Synchronous Endometrial and Ovarian Cancer in Young Women: Case Report and Review of the Literature.
Dogan A, Schultheis B, Rezniczek GA, Hilal Z, Cetin C, Häusler G, Tempfer CB
Anticancer Res 2017 Mar;37(3):969-978. doi: 10.21873/anticanres.11406. PMID: 28314254
A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review.
Shoji T, Takatori E, Murakami K, Kaido Y, Takeuchi S, Kikuchi A, Sugiyama T
J Ovarian Res 2016 Aug 11;9(1):48. doi: 10.1186/s13048-016-0255-6. PMID: 27514842Free PMC Article
Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Winter-Roach BA, Kitchener HC, Lawrie TA
Cochrane Database Syst Rev 2012 Mar 14;3(3):CD004706. doi: 10.1002/14651858.CD004706.pub4. PMID: 22419298Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity